Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis

Background: Heart failure with improved ejection fraction (HFimpEF) is classified as a new type of heart failure, and its prevalence and prognosis are not consistent in previous studies. There is no systematic review and meta-analysis regarding the prevalence and prognosis of the HFimpEF.Method: A s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yibo He, Yihang Ling, Wei Guo, Qiang Li, Sijia Yu, Haozhang Huang, Rongting Zhang, Zhiwen Gong, Jiaxuan Liu, Liyi Mo, Shixin Yi, Disheng Lai, Younan Yao, Jin Liu, Jiyan Chen, Yong Liu, Shiqun Chen
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	heart failure recovered or improved ejection fraction mortality hospitalization meta-analysis Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/cb01cc868f384ef2a8907ba34f95ec5e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb01cc868f384ef2a8907ba34f95ec5e
record_format	dspace
spelling	oai:doaj.org-article:cb01cc868f384ef2a8907ba34f95ec5e2021-12-01T00:05:50ZPrevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis2297-055X10.3389/fcvm.2021.757596https://doaj.org/article/cb01cc868f384ef2a8907ba34f95ec5e2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.757596/fullhttps://doaj.org/toc/2297-055XBackground: Heart failure with improved ejection fraction (HFimpEF) is classified as a new type of heart failure, and its prevalence and prognosis are not consistent in previous studies. There is no systematic review and meta-analysis regarding the prevalence and prognosis of the HFimpEF.Method: A systematic search was performed in MEDLINE, EMBASE, and Cochrane Library from inception to May 22, 2021 (PROSPERO registration: CRD42021260422). Studies were included for analysis if the prognosis of mortality or hospitalization were reported in HFimpEF or in patients with heart failure with recovered ejection fraction (HFrecEF). The primary outcome was all-cause mortality. Cardiac hospitalization, all-cause hospitalization, and composite events of mortality and hospitalization were considered as secondary outcomes.Result: Nine studies consisting of 9,491 heart failure patients were eventually included. During an average follow-up of 3.8 years, the pooled prevalence of HFimpEF was 22.64%. HFimpEF had a lower risk of mortality compared with heart failure patients with reduced ejection fraction (HFrEF) (adjusted HR: 0.44, 95% CI: 0.33–0.60). HFimpEF was also associated with a lower risk of cardiac hospitalization (HR: 0.40, 95% CI: 0.20–0.82) and the composite endpoint of mortality and hospitalization (HR: 0.56, 95% CI: 0.44–0.73). Compared with patients with preserved ejection fraction (HFpEF), HFimpEF was associated with a moderately lower risk of mortality (HR: 0.42, 95% CI: 0.32–0.55) and hospitalization (HR: 0.73, 95% CI: 0.58–0.92).Conclusion: Around 22.64% of patients with HFrEF would be treated to become HFimpEF, who would then obtain a 56% decrease in mortality risk. Meanwhile, HFimpEF is associated with lower heart failure hospitalization. Further studies are required to explore how to promote left ventricular ejection fraction improvement and improve the prognosis of persistent HFrEF in patients.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021260422, identifier: CRD42021260422.Yibo HeYihang LingWei GuoQiang LiSijia YuHaozhang HuangRongting ZhangZhiwen GongZhiwen GongJiaxuan LiuJiaxuan LiuLiyi MoLiyi MoShixin YiDisheng LaiYounan YaoJin LiuJiyan ChenYong LiuShiqun ChenFrontiers Media S.A.articleheart failurerecovered or improved ejection fractionmortalityhospitalizationmeta-analysisDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	heart failure recovered or improved ejection fraction mortality hospitalization meta-analysis Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	heart failure recovered or improved ejection fraction mortality hospitalization meta-analysis Diseases of the circulatory (Cardiovascular) system RC666-701 Yibo He Yihang Ling Wei Guo Qiang Li Sijia Yu Haozhang Huang Rongting Zhang Zhiwen Gong Zhiwen Gong Jiaxuan Liu Jiaxuan Liu Liyi Mo Liyi Mo Shixin Yi Disheng Lai Younan Yao Jin Liu Jiyan Chen Yong Liu Shiqun Chen Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
description	Background: Heart failure with improved ejection fraction (HFimpEF) is classified as a new type of heart failure, and its prevalence and prognosis are not consistent in previous studies. There is no systematic review and meta-analysis regarding the prevalence and prognosis of the HFimpEF.Method: A systematic search was performed in MEDLINE, EMBASE, and Cochrane Library from inception to May 22, 2021 (PROSPERO registration: CRD42021260422). Studies were included for analysis if the prognosis of mortality or hospitalization were reported in HFimpEF or in patients with heart failure with recovered ejection fraction (HFrecEF). The primary outcome was all-cause mortality. Cardiac hospitalization, all-cause hospitalization, and composite events of mortality and hospitalization were considered as secondary outcomes.Result: Nine studies consisting of 9,491 heart failure patients were eventually included. During an average follow-up of 3.8 years, the pooled prevalence of HFimpEF was 22.64%. HFimpEF had a lower risk of mortality compared with heart failure patients with reduced ejection fraction (HFrEF) (adjusted HR: 0.44, 95% CI: 0.33–0.60). HFimpEF was also associated with a lower risk of cardiac hospitalization (HR: 0.40, 95% CI: 0.20–0.82) and the composite endpoint of mortality and hospitalization (HR: 0.56, 95% CI: 0.44–0.73). Compared with patients with preserved ejection fraction (HFpEF), HFimpEF was associated with a moderately lower risk of mortality (HR: 0.42, 95% CI: 0.32–0.55) and hospitalization (HR: 0.73, 95% CI: 0.58–0.92).Conclusion: Around 22.64% of patients with HFrEF would be treated to become HFimpEF, who would then obtain a 56% decrease in mortality risk. Meanwhile, HFimpEF is associated with lower heart failure hospitalization. Further studies are required to explore how to promote left ventricular ejection fraction improvement and improve the prognosis of persistent HFrEF in patients.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021260422, identifier: CRD42021260422.
format	article
author	Yibo He Yihang Ling Wei Guo Qiang Li Sijia Yu Haozhang Huang Rongting Zhang Zhiwen Gong Zhiwen Gong Jiaxuan Liu Jiaxuan Liu Liyi Mo Liyi Mo Shixin Yi Disheng Lai Younan Yao Jin Liu Jiyan Chen Yong Liu Shiqun Chen
author_facet	Yibo He Yihang Ling Wei Guo Qiang Li Sijia Yu Haozhang Huang Rongting Zhang Zhiwen Gong Zhiwen Gong Jiaxuan Liu Jiaxuan Liu Liyi Mo Liyi Mo Shixin Yi Disheng Lai Younan Yao Jin Liu Jiyan Chen Yong Liu Shiqun Chen
author_sort	Yibo He
title	Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
title_short	Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
title_full	Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
title_fullStr	Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
title_full_unstemmed	Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis
title_sort	prevalence and prognosis of hfimpef developed from patients with heart failure with reduced ejection fraction: systematic review and meta-analysis
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/cb01cc868f384ef2a8907ba34f95ec5e
work_keys_str_mv	AT yibohe prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT yihangling prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT weiguo prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT qiangli prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT sijiayu prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT haozhanghuang prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT rongtingzhang prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT zhiwengong prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT zhiwengong prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT jiaxuanliu prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT jiaxuanliu prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT liyimo prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT liyimo prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT shixinyi prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT dishenglai prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT younanyao prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT jinliu prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT jiyanchen prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT yongliu prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis AT shiqunchen prevalenceandprognosisofhfimpefdevelopedfrompatientswithheartfailurewithreducedejectionfractionsystematicreviewandmetaanalysis
_version_	1718406164016791552

Prevalence and Prognosis of HFimpEF Developed From Patients With Heart Failure With Reduced Ejection Fraction: Systematic Review and Meta-Analysis

Ejemplares similares